InHandPlus
InHandPlus is a South Korea-based digital health company that builds an AI-powered, proprietary smartwatch platform to passively monitor medication adherence and generate real-world evidence, serving pharmaceutical companies, CROs, hospitals, and welfare centers across Korea, the U.S., and the UK.
- Company typePrivate
- Founded2019
- HeadquartersYeoksamdong, South Korea
- Headcount11–50
- GTM typeB2B and B2C
- OfferingSoftware
What InHandPlus does
InHandPlus Inc. (인핸드플러스 주식회사), a South Korea-based company founded in March 2019, builds an AI-powered medication adherence and digital healthcare platform anchored by a proprietary smartwatch. The core technology combines a company-manufactured smartwatch that passively collects sensor data (steps, heart rate, falls, medication-handling events) with on-device computer vision AI that detects and classifies objects placed in the user's hand to identify pill-taking behavior, polypharmacy patterns, and adverse events without requiring active user compliance. A companion mobile app and web dashboard deliver medication reminders, real-time communication among patients, clinicians, and family members, and real-world evidence (RWE) data capture. Factory production of the AI Watch was completed in July 2023 following initial mass production in September 2021.
The company monetizes through proprietary smartwatch hardware sales plus subscription/licensing of its digital healthcare platform to pharmaceutical companies, clinical research organizations (CROs), hospitals, and welfare centers. GTM is dual-motion: enterprise field sales targeting pharma and CROs (anchored by an MEDIDATA MOU signed August 2024 and U.S. clinical trial market entry in January 2024) and product-led growth to individual patients for personal medication management. Strategic partnerships with the Korea Public Procurement Service (Oct 2024), Infineon Technologies (Jul 2025), Oxford University (Jul 2025), and Probio Corporation (Jan 2025) support public-sector access, global hardware supply, and clinical validation.
InHandPlus is a privately held, venture-backed company (Pre-A in November 2020; Series A in May 2023) led by Representative Director Lee Hwi-won (이휘원). Headquartered in Pohang with a Seoul office, it operates across South Korea, the United States, and the United Kingdom. The company has 35+ MOU/partnership agreements, two CES Innovation Awards (2022, 2023), and a September 2025 announcement extending the platform into non-invasive blood glucose monitoring as an adjacent chronic-disease vertical.
InHandPlus firmographics
Firmographics- Name
- InHandPlus
- Legal name
- 인핸드플러스 주식회사 (InHandPlus Inc.)
- Website
- https://inhandplus.com
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- InHandPlus is a South Korea-based digital health company that builds an AI-powered, proprietary smartwatch platform to passively monitor medication adherence and generate real-world evidence, serving pharmaceutical companies, CROs, hospitals, and welfare centers across Korea, the U.S., and the UK.
- Ownership category
- akta.pro rank
InHandPlus industry classification
Industry- Product category
- Digital Healthcare / Medication Adherence Technology
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (3345)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), Measuring & Controlling Devices, Nec (3829)
- akta.pro primary industry
- Medication Adherence & Smart Drug Delivery (Connected Inhalers, Pens, Pill Dispensers) (HLACAPAH)
- akta.pro secondary industries
- Adherence, Reminders & Engagement Automation (Medication/Follow-up) (HLACAEAJ), Connected Medical Devices & Wearables (Sensors, Patches, Implantables) (HLACAPAB), Connected Therapeutics & Smart Drug Delivery Monitoring (HLACAFAL)
Keywords
Where InHandPlus is headquartered
LocationHeadquarters
- HQ city
- Yeoksamdong
- HQ country
- South Korea
- HQ region
- Asia
Offices2 records
Markets served
InHandPlus business model
Business model- GTM type
- B2B and B2C
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Supply Chain, Marketing or Sales, Operations
Revenue model
- Proprietary Smartwatch Hardware Sales: Sale of proprietary AI-enabled smartwatches manufactured in-house (factory production started July 2023, mass production since September 2021). Hardware is a core component of the digital healthcare platform.
- Digital Healthcare Platform Subscription / Licensing: SaaS-style platform access via app and web dashboard, providing medication management, health monitoring, and real-time communication tools. Revenue derived from clinical trial operators, healthcare institutions, and patients.
- Clinical Trial Technology Services: Provision of medication adherence monitoring solutions to pharmaceutical companies and clinical research organizations conducting clinical trials. Generates real-world evidence including medication history, symptoms, and adverse events. Expanded into U.S. clinical trial market in 2024.
Go-to-market motion2 records
Distribution channels3 records
Marketing channels4 records
InHandPlus product offering
Product offeringCore offering
InHandPlus develops and sells a proprietary AI-enabled smartwatch combined with a mobile app and web dashboard that form an integrated digital healthcare platform for medication behavior monitoring. The AI solution analyzes smartwatch sensor data to automatically detect what medications users are taking and when, without requiring active user compliance, and generates real-world evidence for clinical trials and personalized healthcare. The platform also supports vital sign monitoring (heart rate, steps, fall detection) and real-time communication among patients, doctors, nurses, and family members.
Product overview
InHandPlus offers a unified digital healthcare platform centered on AI-powered medication management. The core offering consists of a proprietary smartwatch device that collects healthcare sensor data, combined with an AI solution that analyzes medication behaviors through computer vision. The Digital Healthcare Platform integrates the smartwatch with mobile and web applications to provide real-time communication between patients, doctors, nurses, and families. Key features include Ambient AI for passive medication tracking, polypharmacy management, medication alarms, adverse event recording, and vital sign monitoring (step count, heart rate, fall detection). The platform generates real-world evidence data for clinical trials and personalized healthcare insights.
Differentiator
Problem solved
Functional benefit
Products and services
- AI Solution AI-based medication behavior analysis engine that processes data collected from InHandPlus smartwatches to identify when and what medications users are taking, using proprietary computer vision algorithms to detect pills and objects in hand.
- AI Watch (Proprietary Smartwatch) InHandPlus-developed smartwatch with embedded sensors that collects step counts, heart rate, and fall detection data and serves as the hardware foundation for AI medication behavior analysis and the digital healthcare platform.
- Digital Healthcare Platform Integrated platform comprising the AI Watch, mobile app, and web dashboard that delivers data-driven healthcare insights, medication alarms, adverse event and symptom recording (NRS), and real-time communication among patients, doctors, nurses, and families.
- Clinical Trial Medication Adherence Solution Enterprise offering for pharmaceutical companies and CROs that delivers continuous, objective medication adherence monitoring and real-world evidence (medication history, symptoms, adverse events) for clinical trial participants.
Quantifiable outcome
- Improves clinical trial participant adherence by providing objective medication monitoring and real-world evidence generation
- +1 more outcomes
Companies that use InHandPlus
Customer profileNamed customers11 records
Segments3 records
Ideal customer profiles3 records
InHandPlus technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability7 records
Feature4 records
InHandPlus partnerships and signals
Strategic signalPartnerships
24 partnerships are on record, tiered minor and core.
- Non-invasive Blood Glucose Monitoring (R&D)minorNon-invasive blood glucose monitoring development announced September 2025, expanding the health monitoring capabilities of the smartwatch platform.
- Suseo Welfare Center (수서복지관)minorAgreement signed August 2025 for AI solution adoption at the Suseo Welfare Center.
- WegoV Smart Clinical Research ApplicationminorSmart clinical research application partnership announced August 2025.
- Infineon TechnologiescoreStrategic partnership with German semiconductor company Infineon signed July 2025 for global market expansion and smartwatch hardware supply chain cooperation. Infineon provides semiconductor components and global market access.
- Oxford UniversitycoreSmart clinical joint research partnership signed July 2025 with Oxford University for clinical validation and research collaboration on AI medication management.
- Probio CorporationcorePartnership agreement signed January 2025 for collaboration in healthcare data and digital health solutions. Probio Corporation and InHandPlus agreed to jointly develop and promote digital healthcare services.
- AdhesionaminorMOU contract signed November 2024. Nature of collaboration relates to digital healthcare solutions.
- Korea Public Procurement ServicecoreInHandPlus's product designated as an Innovative Product by the Public Procurement Service in October 2024, enabling government and public sector procurement opportunities.
- MEDIDATAcoreMOU contract signed August 2024 with MEDIDATA, a leading clinical trial technology company, to integrate InHandPlus's medication adherence and RWE solutions into MEDIDATA's clinical trial platform.
- Incheon CCEI (Big Wave Program)minorSelected for the Big Wave Program by Incheon CCEI (Culture, Content & Entertainment Industry) in June 2024 for startup growth support.
- Seoul Comprehensive Social Welfare CenterminorMOU contract signed May 2024 to adopt AI healthcare solutions for welfare center patients.
- KT&GminorMOU contract signed February 2024 with KT&G, a major Korean company, for digital healthcare collaboration.
- AI Watch Factory ProductionminorFactory production of AI Watch completed in July 2023, indicating manufacturing partnership for proprietary smartwatch hardware.
- DoBrainminorMOU contract signed February 2023 for AI-driven digital healthcare solutions.
- Tnalee (UK)minorMOU contract signed December 2022 with UK-based Tnalee for digital healthcare collaboration.
- Seoul National University HospitalcoreJoint research conducted from June 2022 with Seoul National University Hospital for clinical validation of AI medication management solution.
- InnovoTherapeuticsminorMOU contract signed April 2022 for digital healthcare solutions in therapeutics.
- CardipointminorMOU contract signed February 2022 for digital healthcare solutions.
- Myungji Social Welfare CenterminorMOU contract signed January 2021 for pilot testing of medication management solution for allergy patients.
- C&R ResearchminorMOU contract signed June 2020 for clinical research technology collaboration.
- Chungnam Sciencecare CenterminorMOU contract signed April 2020 for clinical data and healthcare collaboration.
- Banwol Examination Hospitals NetworkminorMOU contract signed March 2020 for clinical data and patient monitoring collaboration.
- K-waterminorMOU contract signed January 2020 for digital healthcare solutions.
- Soram HospitalminorMOU contract signed June 2019 for digital healthcare solution deployment.
Scale indicators4 records
Recent moves7 records
Expansion highlights7 records
InHandPlus competitors and assessment
Company assessmentDirect peers
- AiCure: AiCure provides AI-powered patient monitoring and medication adherence technology for clinical trials using smartphone cameras. Directly comparable to InHandPlus in using AI to passively verify medication-taking behavior in pharma/CRO settings, though InHandPlus is smartwatch-centric while AiCure uses smartphone.
- AdhereTech: AdhereTech makes connected smart pill bottles that monitor adherence in real time for pharma and patient use. Comparable to InHandPlus in the medication-adherence-monitoring category, though AdhereTech uses packaging-based hardware rather than a wearable.
- etectRx: etectRx manufactures ingestible sensor pills that transmit adherence data from inside the body. A direct clinical-trial-focused competitor to InHandPlus in the digital adherence / RWE space with similar pharma and CRO customer base.
- Propeller Health (ResMed): Propeller Health (acquired by ResMed) makes connected inhaler sensors plus a software platform for respiratory medication adherence. Comparable to InHandPlus as a connected medication adherence + RWE platform serving pharma and providers, though focused on inhaled drugs.
- MedMinder Systems: MedMinder produces smart pill dispensers and an adherence platform for polypharmacy patients and home care. A close peer in the medication management / polypharmacy category InHandPlus targets, with overlapping elderly and chronic-disease patient populations.
Broad incumbents
- Medidata Solutions (Dassault Systèmes): Medidata is the dominant clinical trial technology platform (Rave EDC, eCOA) and a direct partner of InHandPlus. As a broad incumbent, it sets the ecosystem standard and channel for adherence/RWE modules that InHandPlus plugs into, making it both a partner and a competitive ceiling.
- Vivify Health (Optum / UnitedHealth): Vivify Health is an enterprise RPM and connected-care platform used by US health systems and payors. Comparable to InHandPlus's RPM/vitals ambitions but at much larger enterprise scale and broader scope.
- Philips Remote Patient Monitoring: Philips offers enterprise RPM and remote monitoring solutions to hospitals and health systems globally. A broad incumbent that competes for the same digital-health wallet share as InHandPlus's healthcare-institution segment.
Emerging players
- Empatica: Empatica builds medical-grade wearable sensors and AI for health monitoring (epilepsy, sleep, stress) with FDA-cleared devices. An adjacent wearable-health peer focused on vitals/anomaly detection that overlaps InHandPlus's fall-detection and vital-sign monitoring capabilities.
- Blue Spark Technologies: Blue Spark Technologies develops disposable, wearable patient-monitoring patches used in clinical trials and care settings. Comparable to InHandPlus's wearable-based monitoring approach in clinical research, with a different form factor (skin patch) but similar customer base.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
InHandPlus social profiles
Digital presenceInHandPlus financial estimates
Financial estimateRevenue estimate
Valuation estimate
InHandPlus leadership team
Management profileNumber of profiles
Profiles1 record
InHandPlus funding detail
Funding detailFunding overview
Funding rounds2 records
Investors7 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
InHandPlus M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about InHandPlus
What does InHandPlus do?
InHandPlus develops and sells a proprietary AI-enabled smartwatch combined with a mobile app and web dashboard that form an integrated digital healthcare platform for medication behavior monitoring. The AI solution analyzes smartwatch sensor data to automatically detect what medications users are taking and when, without requiring active user compliance, and generates real-world evidence for clinical trials and personalized healthcare. The platform also supports vital sign monitoring (heart rate, steps, fall detection) and real-time communication among patients, doctors, nurses, and family members.
Is InHandPlus a public or private company?
InHandPlus is a private company. It is classified as venture growth investor backed and is currently operating.
When was InHandPlus founded?
InHandPlus was founded in 2019. It employs 11 to 50 people.
Where is InHandPlus based?
InHandPlus is headquartered in Yeoksamdong, South Korea, in the Asia region.
How does InHandPlus make money?
Three revenue lines are on record. Proprietary Smartwatch Hardware Sales are the primary driver. The others are digital Healthcare Platform Subscription / Licensing and clinical Trial Technology Services.
Who are InHandPlus's main competitors?
Direct peers on record are AiCure, AdhereTech, etectRx, Propeller Health (ResMed) and MedMinder Systems. Broad incumbents are Medidata Solutions (Dassault Systèmes), Vivify Health (Optum / UnitedHealth) and Philips Remote Patient Monitoring. Emerging players are Empatica and Blue Spark Technologies.
Does InHandPlus have an API?
No public API is recorded for InHandPlus.
What industry is InHandPlus in?
InHandPlus's product category is Digital Healthcare / Medication Adherence Technology. Its primary akta.pro industry code is HLACAPAH, Medication Adherence & Smart Drug Delivery (Connected Inhalers, Pens, Pill Dispensers), with a secondary code of HLACAEAJ, Adherence, Reminders & Engagement Automation (Medication/Follow-up). Its NAICS code is 334510 and its SIC code is 3841.